OK … so it took us a couple of days to work out why only two centers (at UCSF and UCLA) had been approved to administer the new (to the US) gallium-68 PSMA-11 scans. It wasn’t very smart of us. We should have realized immediately! … READ MORE …
Filed under: Management | Tagged: gallium-68, maunfacture, PSMA, scan | 10 Comments »
Yesterday the US Food and Drug Administration (FDA) gave its approval for the first gallium-68 prostate-specific membrane antigen imaging agent (Ga-67 PSMA-11), for the use in association with positron emission tomography (PET) scanning for the evaluation of men with suspected prostate cancer — and most particularly for those men with high-risk characteristics suggesting the possibility of metastasis, including men with newly diagnosed or recurrent disease. However, here’s the “but”… READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: gallium-68, imaging, PET, PSMA, scan | 5 Comments »
We had previously reported on a presentation by Calais et al. earlier this year. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: Axumin, fluciclovine, fluorine-18, gallium-68, imaging, PET/CT, PSMA, scan | 9 Comments »
According to a presentation given yesterday at the ASCO meeting here in Chicago, PET/CT scanning with 68Ga-PSMA-11 is more accurate than 18F-fluciclovine PET/CT at detecting recurrent prostate cancer in men with early biochemical recurrence following radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: fluciclovine, fluorine-18, gallium-68, PET, PET/CT, scan | 11 Comments »
A research team at the University of California, Los Angeles (UCLA) is seeking participants for a randomized, Phase III, clinical trial of the utility of 68Ga-PSMA-11 PET/CT molecular imaging for planning of salvage radiotherapy after first-line treatment for localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CT, free, gallium-68, PET, PSMA-11, radiation, salvage, scan, SRT, therapy | 4 Comments »
A new article in the journal Cancer Imaging has provided us with an interesting set of “real world” data on the accuracy of gallium-68 PSMA PET/CT scans in the management of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: gallium-68, outc omes, PET/CT, PSMA, real world, scan | 14 Comments »
The “game changer” statement above comes from an independent review of the potential value of gallium-86-labeled prostate-specific molecular antigen (68Ga PSMA) PET scanning in the evaluation of selected men with prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: Diagnosis, gallium-68, PET, prognosis, PSMA, scan, work-up | 4 Comments »
A newly-reported set of data from an Australian clinical research team has now shown that 68Ga PSMA PET/CT scans changed the staging and the management of men after initial diagnosis and prior to first-line treatment compared to traditional CT and bone scanning. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: CT, gallium-68, PET, PSMA, risk, scan | 1 Comment »
A randomized clinical trial of the 68Ga-PSMA-11 PET indicator for men with a recurrence after radical prostatectomy has just been initiated at the University of California Los Angeles (UCLA). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: gallium-68, PET, radiation, salvage, scan, trial | 1 Comment »
The new PSMA-based PET scans provide a way to locate exactly where the cancer has spread to after an unsuccessful prostatectomy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: change, gallium-68, PET, plan, PSMA, radiation, salvage, scan, Treatment | 6 Comments »
The re-treatment of patients with recurrent prostate cancer after initial, first-line treatment for what was initially diagnosed as localized disease can be complicated. Success (i.e., effective re-treatment with curative intent) in the re-treatment of such patients is often dependent on the ability to identify exactly where recurrence has occurred. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: gallium-68, PET, PSMA, radio-guided, recurrent, scan, surgery | 3 Comments »
The gold standard for the clinical relevance of any new test in the management of a specific disease is … Do the results of the test change the way a physician would previously have managed patients? … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: gallium-68, Management, PET/CT, PSMA, recurrence, scan | 3 Comments »
Demonstrating how easy it is to “miss” news that may be important to at least a few members of the prostate cancer community, we have just learned that gallium-68 dotatate ([68Ga]dotatate) PET scanning was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2016 — but not specifically for use in the detection of metastatic or micrometastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer | Tagged: dotatate, gallium-68, NET, neuroendocrine, PSMA | 4 Comments »
As many readers will be aware, there has been a lot of ongoing research using the gallium-68 (68Ga) radioisotope linked to various forms of prostate-specific membrane antigen (PSMA) in concert with PET scan imaging to identify sites of early recurrence of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: copper-64, gallium-68, PET, PSMA, radioligand, scan | 7 Comments »
The question of how much better the varied, new forms of imaging will be in the evaluation of patients with higher-risk prostate cancer both before and after their treatment is a currently “hot topic” in the world of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: choline-C11, gallium-68, imaging, PET/CT, scan, test | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 